Vyvanse and Gabapentin drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Vyvanse (lisdexamfetamine dimesylate) and Gabapentin (gabapentin). Common drug interactions include abdominal discomfort among females and anxiety among males.
The phase IV clinical study analyzes what interactions people have when they take Vyvanse and Gabapentin. It is created by eHealthMe based on reports of 1,328 people who take the same drugs from the FDA, and is updated regularly.
What is Vyvanse?
Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 35,872 Vyvanse users. Check the latest studies of Vyvanse.
What is Gabapentin?
Gabapentin has active ingredients of gabapentin. It is often used in peripheral neuropathy. eHealthMe is studying from 322,990 Gabapentin users. Check the latest studies of Gabapentin.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
1,328 people who take Vyvanse and Gabapentin together, and have interactions are studied.
What are the common drug interactions of Vyvanse and Gabapentin, by gender? *
What are the common drug interactions of Vyvanse and Gabapentin, by age (0-1 to 60+)? *
What are the existing conditions these people have? *
* Approximation only. Some reports may have incomplete information.
Do you take Vyvanse and Gabapentin?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
- Vyvanse (35,872 reports)
- Gabapentin (322,990 reports)
Browse all drug interactions of Vyvanse and Gabapentin:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Vyvanse:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Gabapentin:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Vyvanse and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Gabapentin and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
- Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A, "Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder", Journal of central nervous system disease, 2017 Aug .
- Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD, "Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD", Drug design, development and therapy, 2017 Jan .
- Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
- Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P, "Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials", Drug design, development and therapy, 2013 Jan .
- de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
- Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A, "Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder", Journal of central nervous system disease, 2017 Aug .
- Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD, "Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD", Drug design, development and therapy, 2017 Jan .
- Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
- Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P, "Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials", Drug design, development and therapy, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on lisdexamfetamine dimesylate and gabapentin (the active ingredients of Vyvanse and Gabapentin, respectively), and Vyvanse and Gabapentin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Cosmegen cause Hypertension Aggravated? - 2 seconds ago
- Could Benzonatate cause Pupil Fixed? - 14 seconds ago
- Could Allegra cause Haemophilus Infection? - 15 seconds ago
- Could Montelukast Sodium cause Conjunctivitis? - 15 seconds ago
- Could Adipex-P cause Rashes? - 19 seconds ago
- Could Vytorin cause Wound Dehiscence? - 24 seconds ago
- Drug interactions of Vyvanse and Gabapentin - 24 seconds ago
- Could Vytorin cause Cholecystitis Chronic? - 34 seconds ago
- Drug interactions of Aranesp and Heparin - 36 seconds ago
- Could Humira cause Scleral Discoloration? - 38 seconds ago